Trial Profile
An Open Label, Multiple Dose, Time-lagged, Switch Study to Evaluate the Safety, Tolerability and Activity of Escalating SBR759 Doses in Patients With Chronic Kidney Disease on Hemodialysis
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 23 Oct 2013
Price :
$35
*
At a glance
- Drugs SBR 759 (Primary)
- Indications Hyperphosphataemia
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Novartis Pharmaceuticals Corporation
- 23 Oct 2013 New trial record